Hematologic Oncology

An expert from Augusta University says cancer care should extend beyond treatment and highlights why unmet social needs should be a consideration for survivors of hematologic cancer, especially those with a lower socioeconomic status or who are of a racial or ethnic minority.

Patients who are set to undergo autologous hematopoietic stem cell transplant following induction chemotherapy may have poor mobility across several domains vs an age-matched control group.

Alex Kadhim investigates outcomes in infant patients who receive blood and marrow transplantation.

Expert hematologist-oncologists share their perspective on the broad diagnosis and management of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Patients with B-cell malignancies intolerant to acalabrutinib appeared to derive clinically meaningful benefit from zanubrutinib.

A 3-drug regimen with post-transplant cyclophosphamide may represent a new prophylactic option for well-matched adults with graft-versus-host disease who underwent reduced-intensity transplant.

Among patients with paroxysmal nocturnal hemoglobinuria, crovalimab yielded stable rates of hemolysis control and transfusion avoidance in the phase 3 COMMODORE trial.

The BTK inhibitor pirtobrutinib demonstrated high response rates in pretreated patients with Waldenström macroglobulinemia, according to recent data.

Revumenib, which was given a breakthrough therapy designation by the FDA, may be beneficial in the management of relapsed or refractory KMT2A-rearranged acute leukemia based on data from the phase 1 AUGMENT-101 trial.

ASTCT recently published an article in their journal Nucleus discussing extracorporeal photopheresis compared with acute graft-versus-host disease after receipt of hematopoietic stem cell transplant in children or young adults.

ASTCT recently published an article in their journal Nucleus detailing the use of mesenchymal stromal cells for the treatment of graft-versus-host disease

In her Letter to the Readers, co-editor-in-chief of the journal ONCOLOGY Julie M. Vose, MD, MBA, reviews developments from the fourth annual LEAD Conference for women in hematology and oncology.

Findings from a phase 3 trial assessing nomacopan in patients with hematopoietic stem cell transplant–related thrombotic microangiopathy helped to support a rare pediatric designation from the FDA for the agent.

Patients with histiocytic neoplasms can now receive treatment with cobimetinib following its approval by the FDA.

Closing out their panel on GVHD management, expert hematologist/oncologists share their hope for future evolution in the treatment landscape.

Comprehensive discussion on the pharmacologic treatment armamentarium available for patients with chronic graft vs host disease.

Expert hematologist/oncologists highlight challenges in staging chronic graft vs host disease and share strategies to optimize cGHVD assessment.

After reviewing a clinical scenario of chronic graft vs host disease, panelists consider the importance of different allogeneic transplant types.

Shared insight on treatment approaches toward patients with acute graft vs host disease who experience partial response to frontline therapy.

Focusing on pharmacologic options, expert panelists review frontline treatment strategies for patients with acute graft vs host disease.

Expert hematologist/oncologists share their perspectives on use of biomarkers to help prognosticate graft vs host disease.

Alexis A. Thompson, MD, MPH, reviewed the unmet needs of patients with β-thalassemia who will receive betibeglogene autotemcel.

Pemigatinib had been approved by the FDA as a treatment for patients with FGFR1 rearranged relapsed/refractory myeloid/lymphoid neoplasms.

Based on results of the phase 1/2 iMAGINE trial, the FDA has approved ibrutinib for pediatric patients with chronic graft-versus-host disease.

Centering discussion on a scenario of acute graft vs host disease, expert panelists consider optimal workup of a patient showing signs of GVHD.

Shared insight on the pathophysiology of graft vs host disease, with specific regard for differences between acute GVHD vs chronic GVHD.

Alexis A. Thompson, MD, MPH, reviewed unmet needs for patients with β-thalassemia who may now receive betibeglogene autotemcel.

Alexis A. Thompson, MD, MPH, spoke about the use of betibeglogene autotemcel for patients with β-thalassemia.

Based on results from the phase 3 MOMENTUM trial, the FDA has accepted a new drug application of momelotinib for patients with myelofibrosis.

Pediatric and adult patients who have β -thalassemia and need regular red blood cell infusions may now receive betibeglogene autotemcel, which has been approved by the FDA.